Evidence map›Paper›PMID 28031876›Full record

ArticleFuture science OA2015

Interfacing antibody-based microarrays and digital holography enables label-free detection for loss of cell volume.

Zahra El-Schich, Emmy Nilsson, Anna S Gerdtsson, Christer Wingren, Anette Gjörloff Wingren

Open access · goldAbstract read
In one paragraph

Article in Future science OA, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.7field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 10 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Zahra El-SchichDepartment of Biomedical Science, Health & Society, Malmö University, Malmö, Sweden; Department of Biomedical Science, Health & Society, Malmö University, Malmö, Sweden.
Emmy NilssonDepartment of Biomedical Science, Health & Society, Malmö University, Malmö, Sweden; Department of Biomedical Science, Health & Society, Malmö University, Malmö, Sweden.
Anna S GerdtssonDepartment of Immunotechnology & CREATE Health, Medicon Village, Lund University, Lund, Sweden; Department of Immunotechnology & CREATE Health, Medicon Village, Lund University, Lund, Sweden.
Christer WingrenDepartment of Immunotechnology & CREATE Health, Medicon Village, Lund University, Lund, Sweden; Department of Immunotechnology & CREATE Health, Medicon Village, Lund University, Lund, Sweden.
Anette Gjörloff WingrenDepartment of Biomedical Science, Health & Society, Malmö University, Malmö, Sweden; Department of Biomedical Science, Health & Society, Malmö University, Malmö, Sweden.
Malmö University · SELund University · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundWe introduce the combination of digital holographic microscopy (DHM) and antibody microarrays as a powerful tool to measure morphological changes in specifically antibody-captured cells. The aim of the study was to develop DHM for analysis of cell death of etoposide-treated suspension cells. RESULTS/METHODOLOGY: We demonstrate that the cell number, mean area, thickness and volume were noninvasively measured by using DHM. The cell number was stable over time, but the two cell lines showed changes of cell area and cell irregularity after treatment. The cell volume in etoposide-treated cells was decreased, whereas untreated cells showed stable volume.

conclusionOur results provide proof of concept for using DHM combined with antibody-based microarray technology for detecting morphological changes in captured cells.

Indexed as

antibodycellularholographymicroarrayvolume

Identifiers

PMID28031876
PMCPMC5137949
OpenAlexW1925954556

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.